Oversight and Monitoring of Blood Safety in the United States

The US blood safety vigilance system is composed of a network of interwoven programs, now organized under a formal structure, with the Assistant Secretary of Health and DHHS Blood Safety Committee bearing overall responsibility. It takes advantage of the breadth of expertise and close collaborative relationship of transfusion medicine and infectious disease scientists within and outside of the government. Core elements include an array of ongoing surveillance programs for monitoring established as well as new and emerging infectious agents that may pose a risk to blood safety, and the existence of historical and contemporary repositories of donor and recipient specimens that enable rapid investigation of putative new risks. This report summarizes the historical events that shaped the US blood safety oversight system, reviews the current organization and decision–making processes related to blood safety issues, and highlights key surveillance systems and research programs which monitor the US and global blood supplies for known and potential emerging risks.

[1]  R. Koup,et al.  A 32-bp deletion within the CCR5 locus protects against transmission of parenterally acquired human immunodeficiency virus but does not affect progression to AIDS-defining illness. , 1998, The Journal of infectious diseases.

[2]  P. Brown,et al.  The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy , 1998, Transfusion.

[3]  S. DeArmond,et al.  Surveillance for Creutzfeldt‐Jakob disease among persons with hemophilia , 1998, Transfusion.

[4]  G A Satten,et al.  New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. , 1998, JAMA.

[5]  L. Corash,et al.  Inactivation of Viruses, Bacteria, Protozoa, and Leukocytes in Platelet Concentrates , 1998, Vox sanguinis.

[6]  J. Menitove.  Hemovigilance in the United States of America , 1998, Vox sanguinis.

[7]  L. Williamson,et al.  Haemovigilance: Concept, Europe and UK Initiatives , 1998, Vox sanguinis.

[8]  J. Debeir,et al.  The French Hæmovigilance System , 1998 .

[9]  J. Bethel,et al.  Estimates of Infectious Disease Risk Factors in U.S. Blood Donors , 1998 .

[10]  R. Dodd,et al.  Creutzfeldt‐Jakob disease and transfusion safety: tilting at icebergs? , 1998, Transfusion.

[11]  E. Fiebig,et al.  Quantitation of white cell subpopulations by polymerase chain reaction using frozen whole‐blood samples , 1998, Transfusion.

[12]  H. Webster,et al.  Lymphocyte subset analysis on frozen whole blood. , 1997, Cytometry.

[13]  E. Read,et al.  Seroepidemiology of Trypanosoma cruzi, etiologic agent of Chagas' disease, in US blood donors. , 1997, The Journal of infectious diseases.

[14]  S. Kleinman,et al.  The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. , 1997, Transfusion medicine reviews.

[15]  D. Stram,et al.  Comparative rates of disease progression among persons infected with the same or different HIV-1 strains. The Transfusion Safety Study Group. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[16]  D. Fuchs,et al.  Blood donations and viruses , 1997, The Lancet.

[17]  A. Williams,et al.  Estimates of infectious disease risk factors in US blood donors. Retrovirus Epidemiology Donor Study. , 1997, JAMA.

[18]  M P Busch,et al.  Divergence of HIV‐1 quasispecies in an epidemiologic cluster , 1997, AIDS.

[19]  R. Wesley,et al.  The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease. , 1997, The New England journal of medicine.

[20]  H. Margolis,et al.  Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection. Sentinel Counties Viral Hepatitis Study Team. , 1997, The New England journal of medicine.

[21]  T. Surowy,et al.  An ELISA for detection of antibodies to the E2 protein of GB virus C. , 1997, The Journal of infectious diseases.

[22]  M. Alter,et al.  Hepatitis C virus infection associated with administration of intravenous immune globulin. A cohort study. , 1996, JAMA.

[23]  R. Holman,et al.  Creutzfeldt-Jakob disease in the United States, 1979-1994: using national mortality data to assess the possible occurrence of variant cases. , 1996, Emerging infectious diseases.

[24]  J. Mellors,et al.  The Viral Activation Transfusion Study (VATS): rationale, objectives, and design overview , 1996, Transfusion.

[25]  D. Stram,et al.  Factors influencing human immunodeficiency virus type 1 transmission by blood transfusion. Transfusion Safety Study Group. , 1996, The Journal of infectious diseases.

[26]  S. Kleinman,et al.  The Risk of Transfusion-Transmitted Viral Infections , 1996 .

[27]  J. Hughes,et al.  Addressing emerging microbial threats in the United States. , 1996, JAMA.

[28]  G. Satten,et al.  Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. , 1995, The New England journal of medicine.

[29]  C. Nass,et al.  The Retrovirus Epidemiology Donor Study (REDS): rationale and methods , 1995, Transfusion.

[30]  P. Brown.  Can Creutzfeldt-Jakob disease be transmitted by transfusion? , 1995, Current opinion in hematology.

[31]  L. Leveton,et al.  HIV and the blood supply: an analysis of crisis decision making. , 1995, Transfusion.

[32]  D. Stram,et al.  Human immunodeficiency virus type 1 infection: relationship of risk group and age to rate of progression to AIDS. Transfusion Safety Study Group. , 1995, The Journal of infectious diseases.

[33]  H. Alter.  To C or not to C: these are the questions. , 1995, Blood.

[34]  E. Schiff,et al.  Transfusion transmission of retroviruses: human T‐lymphotropic virus types I and II compared with human immunodeficiency virus type 1 , 1994, Transfusion.

[35]  J J Goedert,et al.  HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990. Multicenter Hemophilia Cohort Study. , 1994, Journal of acquired immune deficiency syndromes.

[36]  A. Muñoz,et al.  The declining risk of post-transfusion hepatitis C virus infection. , 1992, The New England journal of medicine.

[37]  A. Prince,et al.  Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. , 1992, Blood.

[38]  J. Ward,et al.  Human immunodeficiency virus type 1 ‐infected blood donors:behavioral characteristics and reasons for donation , 1991, Transfusion.

[39]  J. Ward,et al.  Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV‐1 antibody screening , 1991, Transfusion.

[40]  S. Azen,et al.  Infection with human immunodeficiency virus type 1 (HIV-1) among recipients of antibody-positive blood donations. , 1990 .

[41]  L. Petersen,et al.  Methodologic approaches to surveillance of HIV infection among blood donors. , 1990, Public health reports.

[42]  M. Houghton,et al.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. , 1989, Science.

[43]  R. Kahn,et al.  Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients. An analysis of the Transfusion-Transmitted Viruses Study. , 1984, Annals of internal medicine.

[44]  H. Alter,et al.  Landmark article Feb 15, 1965: A "new" antigen in leukemia sera. By Baruch S. Blumberg, Harvey J. Alter, and Sam Visnich. , 1984, JAMA.

[45]  R. Purcell,et al.  Donor transaminase and recipient hepatitis. Impact on blood transfusion services. , 1981, JAMA.

[46]  R. Kahn,et al.  Serum alanine aminotransferase of donors in relation to the risk of non-A,non-B hepatitis in recipients: the transfusion-transmitted viruses study. , 1981, The New England journal of medicine.

[47]  R. Purcell,et al.  NON-A, NON-B POST-TRANSFUSION HEPATITIS , 1977, The Lancet.

[48]  R. Purcell,et al.  Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors. , 1972, Annals of internal medicine.

[49]  H. Alter,et al.  A "NEW" ANTIGEN IN LEUKEMIA SERA. , 1965, JAMA.

[50]  P. Beeson.  JAUNDICE OCCURRING ONE TO FOUR MONTHS AFTER TRANSFUSION OF BLOOD OR PLASMA: REPORT OF SEVEN CASES , 1943 .

[51]  H. Moore,et al.  Red blood cell transfusions contaminated with Yersinia enterocolitica--United States, 1991-1996, and initiation of a national study to detect bacteria-associated transfusion reactions. , 1997, MMWR. Morbidity and mortality weekly report.

[52]  M. Manco‐Johnson,et al.  Hepatitis A among persons with hemophilia who received clotting factor concentrate--United States, September-December 1995. , 1996, MMWR. Morbidity and mortality weekly report.

[53]  Update on acquired immune deficiency syndrome (AIDS) among patients with hemophilia A. , 1983, Connecticut medicine.

[54]  H. Goldman,et al.  Possible transfusion-associated acquired immune deficiency syndrome (AIDS) - California. , 1982, MMWR. Morbidity and mortality weekly report.